Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EXELIXIS, INC. Director's Dealing 2023

Dec 15, 2023

30561_dirs_2023-12-14_e3670d26-a7c7-4de4-92ab-9cb66f16c767.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2023-12-12

Reporting Person: Haley Patrick J. (EVP, Commercial)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-12-12 Common Stock S 14149 $22.50 Disposed 307687 Direct
2023-12-14 Common Stock M 50000 $16.29 Acquired 357687 Direct
2023-12-14 Common Stock S 50000 $23.35 Disposed 307687 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-12-14 Option (right to buy) $16.29 M 50000 Disposed 2023-12-18 Common Stock (50000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 23539 Indirect
Common Stock 10648 Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2023.

F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.50 to $22.52. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F3: Includes 200,242 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

F4: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.01 to $23.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.

F5: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of December 11, 2023.

F6: The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 19, 2020.